A trial of personalized CAR T cells against one of the common glioblastoma targets, including EGFRvIII, IL13Ra2, HER2, EphA2, CD133, and GD2, has published initial results for a cohort of three patients who received EphA2-CART administered in a single dose intravenously [87]. This evidence concerns the gene ERBB2 and glioblastoma.